Abstract
Introduction: Although increased cholesterol level has been acknowledged as a risk factor for dementia, evidence synthesis based on published data has yielded mixed results. This is especially relevant in older adults where individual studies report non-linear relationships between cholesterol and cognition and, in some cases, find higher cholesterol associated with a lower risk of subsequent cognitive decline or dementia. Prior evidence synthesis based on published results has not allowed us to focus on older adults or to standardize analyses across studies. Given our ageing population, an increased risk of dementia in older adults, and the need for proportionate treatment in this age group, an individual participant data (IPD) meta-analysis is timely. Method: We combined data from 8 studies and over 21,000 participants aged 60 years and over in a 2-stage IPD to examine the relationship between total, high-density, and low-density lipoprotein (HDL and LDL) cholesterol and subsequent incident dementia or cognitive decline, with the latter categorized using a reliable change index method. Results: Meta-analyses found no relationship between total, HDL, or LDL cholesterol (per millimoles per litre increase) and risk of cognitive decline in this older adult group averaging 76 years of age. For total cholesterol and cognitive decline: odds ratio (OR) 0.93 (95% confidence interval [CI] 0.86: 1.01) and for incident dementia: OR 1.01 [95% CI 0.89: 1.13]. This was not altered by rerunning the analyses separately for statin users and non-users or by the presence of an APOE e4 allele. Conclusion: There were no clear consistent relationships between cholesterol and cognitive decline or dementia in this older adult group, nor was there evidence of effect modification by statin use. Further work is needed in younger populations to understand the role of cholesterol across the life-course and to identify any relevant intervention points. This is especially important if modification of cholesterol is to be further evaluated for its potential influence on risk of cognitive decline or dementia.
References
1.
Kivipelto
M
, Ngandu
T
, Fratiglioni
L
, Viitanen
M
, Kåreholt
I
, Winblad
B
, Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease
. Arch Neurol
. 2005 Oct
;62
(10
):1556
–60
. .2.
Whitmer
RA
, Sidney
S
, Selby
J
, Johnston
SC
, Yaffe
K
. Midlife cardiovascular risk factors and risk of dementia in late life
. Neurology
. 2005 Jan 25
;64
(2
):277
–81
. .3.
Solomon
A
, Kivipelto
M
, Wolozin
B
, Zhou
J
, Whitmer
RA
. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later
. Dement Geriatr Cogn Disord
. 2009
;28
(1
):75
–80
. .4.
Mielke
MM
, Zandi
PP
, Shao
H
, Waern
M
, Östling
S
, Guo
X
, The 32-year relationship between cholesterol and dementia from midlife to late life
. Neurology
. 2010
;75
(21
):1888
–95
. .5.
Anstey
KJ
, Ashby-Mitchell
K
, Peters
R
. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis
. J Alzheimers Dis
. 2017
;56
(1
):215
–28
. .6.
Anstey
KJ
, Ashby-Mitchell
K
, Peters
R
. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis
. J Alzheimers Dis
. 2017
;56
:215
–28
. .7.
Yoshitake
T
, Kiyohara
Y
, Kato
I
, Ohmura
T
, Iwamoto
H
, Nakayama
K
, Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama study
. Neurology
. 1995
;45
(6
):1161
–8
. .8.
Tan
ZS
, Seshadri
S
, Beiser
A
, Wilson
PW
, Kiel
DP
, Tocco
M
, Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham study
. Arch Intern Med
. 2003 May 12
;163
(9
):1053
–7
. .9.
Weverling-Rijnsburger
AW
, Blauw
GJ
, Lagaay
AM
, Knook
DL
, Meinders
AE
, Westendorp
RG
. Total cholesterol and risk of mortality in the oldest old
. Lancet
. 1997 Oct 18
;350
(9085
):1119
–23
. .10.
Mielke
MM
, Zandi
PP
, Sjögren
M
, Gustafson
D
, Ostling
S
, Steen
B
, High total cholesterol levels in late life associated with a reduced risk of dementia
. Neurology
. 2005 May 24
;64
(10
):1689
–95
. .11.
Li
S
, Zheng
M
, Gao
S
. Joint modeling of longitudinal cholesterol measurements and time to onset of dementia in an elderly African American Cohort
. Biostat Epidemiol
. 2017 Jan 1
;1
(1
):148
–60
. .12.
Montesanto
A
, Pellegrino
D
, Geracitano
S
, La Russa
D
, Mari
V
, Garasto
S
, Cardiovascular risk profiling of long-lived people shows peculiar associations with mortality compared with younger individuals
. Geriatr Gerontol Int
. 2019 Feb
;19
(2
):165
–70
. .13.
Wendell
CR
, Zonderman
AB
, Katzel
LI
, Rosenberger
WF
, Plamadeala
VV
, Hosey
MM
, Nonlinear associations between plasma cholesterol levels and neuropsychological function
. Neuropsychology
. 2016 Nov
;30
(8
):980
–7
. .14.
Marcum
ZA
, Walker
R
, Bobb
JF
, Sin
MK
, Gray
SL
, Bowen
JD
, Serum cholesterol and incident Alzheimer’s disease: findings from the adult changes in thought study
. J Am Geriatr Soc
. 2018 Dec
;66
(12
):2344
–52
. .15.
Fanshawe
TR
, Perera
R
. Conducting one-stage IPD meta-analysis: which approach should I choose?
BMJ Evid Based Med
. 2019
;24
(5
):190
. .16.
Hensel
A
, Angermeyer
MC
, Riedel-Heller
SG
. Measuring cognitive change in older adults: reliable change indices for the mini-mental state examination
. J Neurol Neurosurg Psychiatry
. 2007
;78
(12
):1298
–303
. .17.
Staessen
JA
, Fagard
R
, Thijs
L
, Celis
H
, Arabidze
GG
, Birkenhäger
WH
, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
. Lancet
. 1997 Sep 13
;350
(9080
):757
–64
. .18.
3C Study Group
.. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population
. Neuroepidemiology
. 2003 Nov–Dec
;22
(6
):316
–25
. .19.
Collerton
J
, Barrass
K
, Bond
J
, Eccles
M
, Jagger
C
, James
O
, The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol
. BMC Geriatr
. 2007 Jun 26
;7
:14
. .20.
Saukkonen
T
, Jokelainen
J
, Timonen
M
, Cederberg
H
, Laakso
M
, Härkönen
P
, Prevalence of metabolic syndrome components among the elderly using three different definitions: a cohort study in Finland
. Scand J Prim Health Care
. 2012
;30
(1
):29
–34
. .21.
van Peet
PG
, Drewes
YM
, de Craen
AJ
, Westendorp
RG
, Gussekloo
J
, de Ruijter
W
. Prognostic value of cardiovascular disease status: the Leiden 85-plus study
. Age
. 2013
;35
(4
):1433
–44
. .22.
Skoog
I
, Waern
M
, Duberstein
P
, Blennow
K
, Zetterberg
H
, Börjesson-Hanson
A
, A 9-year prospective population-based study on the association between the APOE*E4 allele and late-life depression in Sweden
. Biol Psychiatry
. 2015 Nov 15
;78
(10
):730
–6
. .23.
Joas
E
, Guo
X
, Kern
S
, Östling
S
, Skoog
I
. Sex differences in time trends of blood pressure among Swedish septuagenarians examined three decades apart: a longitudinal population study
. J Hypertens
. 2017
;35
(7
):1424
. .24.
Forette
F
, Seux
ML
, Staessen
JA
, Thijs
L
, Birkenhäger
WH
, Babarskiene
MR
, Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
. Lancet
. 1998 Oct 24
;352
(9137
):1347
–51
. .25.
Forette
F
, Seux
ML
, Staessen
JA
, Thijs
L
, Babarskiene
MR
, Babeanu
S
, The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study
. Arch Intern Med
. 2002 Oct 14
;162
(18
):2046
–52
. .26.
Houx
PJ
, Shepherd
J
, Blauw
GJ
, Murphy
MB
, Ford
I
, Bollen
EL
, Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk
. J Neurol Neurosurg Psychiatry
. 2002 Oct
;73
(4
):385
–9
. .27.
Shepherd
J
, Blauw
GJ
, Murphy
MB
, Bollen
EL
, Buckley
BM
, Cobbe
SM
, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
. Lancet
. 2002 Nov 23
;360
(9346
):1623
–30
. .28.
Beckett
NS
, Peters
R
, Fletcher
AE
, Staessen
JA
, Liu
L
, Dumitrascu
D
, Treatment of hypertension in patients 80 years of age or older
. N Engl J Med
. 2008
;358
(18
):1887
–98
. .29.
Peters
R
, Beckett
N
, Forette
F
, Tuomilehto
J
, Clarke
R
, Ritchie
C
, Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial
. Lancet Neurol
. 2008 Aug
;7
(8
):683
–9
. .30.
Bosch
J
, O'Donnell
M
, Swaminathan
B
, Lonn
EM
, Sharma
M
, Dagenais
G
, Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study
. Neurology
. 2019 Mar 26
;92
(13
):e1435
–e46
. .31.
Trompet
S
, van Vliet
P
, de Craen
AJ
, Jolles
J
, Buckley
BM
, Murphy
MB
, Pravastatin and cognitive function in the elderly. Results of the PROSPER study
. J Neurol
. 2010 Jan
;257
(1
):85
–90
. .32.
Prince
M
, Albanese
E
, Guerchet
M
, Prina
M
. World Alzheimer Report 2014: dementia and risk reduction an analysis of protective and modifiable factors
. London
: Alzheimer’s Disease International
; 2014
.33.
Peters
R
, Peters
J
, Booth
A
, Anstey
KJ
. Trajectory of blood pressure, body mass index, cholesterol and incident dementia: systematic review
. Br J Psychiatry
. 2020
;216
(1
):16
–28
. .34.
Anstey
KJ
, Ee
N
, Eramudugolla
R
, Jagger
C
, Peters
R
. A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence
. J Alzheimers Dis
. 2019
;70
(s1
):S165
–86
. .35.
Schilling
S
, Tzourio
C
, Soumaré
A
, Kaffashian
S
, Dartigues
JF
, Ancelin
ML
, Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C study: a longitudinal, population-based prospective cohort study
. PLoS Med
. 2017 Mar
;14
(3
):e1002265
. .36.
McGuinness
B
, Craig
D
, Bullock
R
, Passmore
P
. Statins for the prevention of dementia
. Cochrane Database Syst Rev
. 2016
(1
):CD003160
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
